

# Poly ADP-Ribose Polymerase PARP Inhibitors Report 2025 – For Strategy Officers And Market Intelligence Teams

*The Business Research Company's Poly ADP-Ribose Polymerase PARP Inhibitors Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED KINGDOM, July 24, 2025

/EINPresswire.com/ -- How Big Is The Global Poly ADP-Ribose Polymerase PARP Inhibitors Market Expected To Grow?



The Business  
Research Company

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors  
Global Market Report 2025

The [poly adp-ribose polymerase parp inhibitors market size](#) has witnessed accelerated growth in recent times and anticipates a promising trend for the foreseeable future. The market size has escalated rapidly from \$5.58 billion in 2024 to \$6.41 billion in 2025, reflecting a compound

annual growth rate CAGR of 14.9%. These tremendous growth projections during the historic period are influenced by factors such as rising healthcare expenditure, burgeoning demand for maintenance therapies, increasing application in combination therapies, growing inclination towards a personalized medicine approach, and escalating investment in the oncology pipeline.

“

The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034”

*The Business Research  
Company*

What Does The Future Of The Poly ADP-Ribose Polymerase PARP Inhibitors Market Entail?

The market size for poly adp-ribose polymerase parp inhibitors is predicted to witness a substantial growth spurt in the nearing years, expectedly reaching \$11.05 billion by 2029 at a CAGR of 14.6%. The anticipated growth during the forecast period can be attributed to the increasing prevalence of cancer, a growing adoption rate of targeted therapies, a swelling geriatric demographic, increased awareness about genetic testing, and a increasing activity in clinical trials.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24662&type=smp>

What Are The Key Factors Driving The Growth Of The Poly ADP-Ribose Polymerase PARP Inhibitors Market?

One of the key contributing factors propelling the growth of the polyADP-ribose polymerase PARP inhibitors market forward is the escalating number of breast cancer cases. Breast cancer is a condition wherein abnormal cells in the breast grow in an uncontrollable manner, potentially forming a tumor and metastasizing to other body parts. The growth in breast cancer incidences arises from lifestyle-related factors such as obesity, inactivity, and alcohol consumption, which raise estrogen levels and promote tumor growth. PolyADP-ribose polymerase PARP inhibitors aid in breast cancer treatment by attacking cancer cells with DNA repair deficiencies, especially those with BRCA mutations. By inhibiting DNA repair, they reduce tumor growth, thereby offering a targeted treatment that improves patient outcomes while minimizing damage to healthy cells.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitors-global-market-report>

Which Are The Key Players In The Poly ADP-Ribose Polymerase PARP Inhibitors Market?

Leading players in the poly ADP-ribose polymerase PARP inhibitors market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Genentech Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., BeiGene, EMD Serono, Myriad Genetics, Clovis Oncology Inc., Repare Therapeutics Inc., Karyopharm Therapeutics, Checkpoint Therapeutics Inc.

What Are The Emerging Trends In The Poly ADP-Ribose Polymerase PARP Inhibitors Market?

Major corporations in the poly ADP-ribose polymerase PARP inhibitors market are channeling their focus on the development of innovative solutions, such as combination therapies, in order to heighten drug efficacy, lower side effects, and extend therapeutic applications beyond oncology.

How Is The [Poly ADP-Ribose Polymerase PARP Inhibitors Market Segmented?](#)

The poly ADP-ribose polymerase PARP inhibitors market is divided as follows:

- 1 By Drug Type: Niraparib, Olaparib, Rucaparib, Talazoparib, Veliparib, Other Drug Types
- 2 By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies
- 3 By Application: Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Other Applications
- 4 By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

What Are The Regional Insights Into The Poly ADP-Ribose Polymerase PARP Inhibitors Market?

North America dominated the polyADP-ribose polymerase PARP inhibitors market in 2024. However, Asia-Pacific is likely to emerge as the fastest-growing region during the forecast period. The regions covered in the report span Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Proteasome Inhibitors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report>

Alpha Glucosidase Inhibitors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report>

Proton Pump Inhibitors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report>

#### About The Business Research Company:

The Business Research Company, with more than 15000+ reports from 27 industries covering 60+ geographies, has built a reputation for providing comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic approach of in-depth secondary research and unique insights from industry leaders, you get the information you need to stay ahead of the competition.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fI0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 7882 955267

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[LinkedIn](#)  
[Facebook](#)  
[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/829001810>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.